Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
TAKDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| July 6, 2026 | $0.31 | 2026-03-31 | 2026-03-31 |
| December 11, 2025 | $0.32 | 2025-09-30 | 2025-09-30 |
| July 7, 2025 | $0.34 | 2025-03-31 | 2025-03-31 |
| December 12, 2024 | $0.33 | 2024-09-30 | 2024-09-30 |
| July 8, 2024 | $0.29 | 2024-03-27 | 2024-03-28 |
Dividends Summary
- Consistent Payer: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) has rewarded shareholders with 15 dividend payments over the past 7 years.
- Total Returned Value: Investors who held TAK shares during this period received a total of $5.36 per share in dividend income.
- Latest Payout: The most recent dividend of $0.31/share was paid 12 days ago, on July 6, 2026.
- Dividend Growth: Since 2019, the dividend payout has decreased by 26.1%, from $0.42 to $0.31.
Company News
ResearchAndMarkets.com released a comprehensive report analyzing over 1,859 clinical-stage pharmaceutical and biotechnology partnership deals announced since 2020. The report provides detailed financial terms, deal structures, contract documents, and insights into negotiation dynamics for clinical-stage drug development collaborations, serving as...
The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% ...
Takeda Pharmaceutical's AI-developed drug zasocitinib demonstrated statistical superiority over Bristol-Myers Squibb's deucravacitinib in a Phase 3 head-to-head trial for plaque psoriasis treatment. Zasocitinib achieved over 35% complete skin clearance (PASI 100) at week 16, more than 2.5 times the response rate of the competitor drug. The compan...
Ascentage Pharma announced Phase Ib study results showing olverembatinib combined with blinatumomab demonstrated encouraging clinical activity in patients with relapsed/refractory Ph+ BCP-ALL or CML-LBP, with 91% achieving complete response and manageable safety profile. The company presented six studies across three key assets at the 2026 ASCO A...
Ascentage Pharma presented updated clinical data at ASCO 2026 showing olverembatinib achieved a 91.3% complete cytogenetic response rate and 60.9% major molecular response rate at cycle 24 in CML-CP patients as second-line therapy. The drug demonstrated a stable safety profile with no new safety signals, supporting its potential role in treating ...
